Non-ablative fractional laser assists cutaneous delivery of small- and macro-molecules with minimal bacterial infection risk

Woan Ruoh Lee, Shing Chuan Shen, Ibrahim A. Aljuffali, Yin Ku Lin, Chang Wei Huang, Jia You Fang

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Use of the ablative laser has been approved to enhance topical drug penetration. Investigation into the usefulness of the non-ablative laser for assisting drug delivery is very limited. In this study, we explored the safety and efficacy of the non-ablative fractional erbium:glass (Er:glass) laser as an enhancement approach to promote drug permeation. Both pig and nude mouse skins were employed as transport barriers. We histologically examined the skin structure after laser exposure. The permeants of 5-aminolevulinic acid (ALA), imiquimod, tretinoin, peptide, dextrans and quantum dots (QD) were used to evaluate in vitro and in vivo skin passage. The fractional laser selectively created an array of photothermal dots deep into the dermis with the preservation of the stratum corneum and epidermis. The barrier function of the skin could be recovered 8–60 h post-irradiation depending on the laser spot densities. The application of the laser caused no local infection of Staphylococcus aureus and Pseudomonas aeruginosa. Compared to intact skin, ALA flux was enhanced up to 1200-fold after laser exposure. The penetration enhancement level by the laser was decreased following the increase of permeant lipophilicity. The skin accumulation of tretinoin, an extremely lipophilic drug, showed only a 2-fold elevation by laser irradiation. The laser promoted peptide penetration 10-fold compared to the control skin. Skin delivery of dextrans with a molecular weight (MW) of at least 40 kDa could be achieved with the Er:glass laser. QD with a diameter of 20 nm penetrated into the skin with the assistance of the non-ablative laser. The confocal microscopic images indicated the perpendicular and lateral diffusions of dextrans and nanoparticles via laser-created microscopic thermal zones. Controlled Er:glass laser irradiation offers a valid enhancement strategy to topically administer the permeants with a wide MW and lipophilicity range.

Original languageEnglish
Pages (from-to)1-10
Number of pages10
JournalEuropean Journal of Pharmaceutical Sciences
Volume92
DOIs
Publication statusPublished - Sep 20 2016

Fingerprint

Bacterial Infections
Lasers
Skin
Erbium
Dextrans
Glass
Quantum Dots
Aminolevulinic Acid
Tretinoin
Pharmaceutical Preparations
imiquimod
Molecular Weight
Peptides
Dermis
Nude Mice
Epidermis
Nanoparticles
Cornea
Pseudomonas aeruginosa
Staphylococcus aureus

Keywords

  • Cutaneous delivery
  • Macromolecule
  • Nanoparticle
  • Non-ablative fractional laser
  • Small-molecule drug

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Non-ablative fractional laser assists cutaneous delivery of small- and macro-molecules with minimal bacterial infection risk. / Lee, Woan Ruoh; Shen, Shing Chuan; Aljuffali, Ibrahim A.; Lin, Yin Ku; Huang, Chang Wei; Fang, Jia You.

In: European Journal of Pharmaceutical Sciences, Vol. 92, 20.09.2016, p. 1-10.

Research output: Contribution to journalArticle

@article{998bbb0d319e42a099072a7474a7b52f,
title = "Non-ablative fractional laser assists cutaneous delivery of small- and macro-molecules with minimal bacterial infection risk",
abstract = "Use of the ablative laser has been approved to enhance topical drug penetration. Investigation into the usefulness of the non-ablative laser for assisting drug delivery is very limited. In this study, we explored the safety and efficacy of the non-ablative fractional erbium:glass (Er:glass) laser as an enhancement approach to promote drug permeation. Both pig and nude mouse skins were employed as transport barriers. We histologically examined the skin structure after laser exposure. The permeants of 5-aminolevulinic acid (ALA), imiquimod, tretinoin, peptide, dextrans and quantum dots (QD) were used to evaluate in vitro and in vivo skin passage. The fractional laser selectively created an array of photothermal dots deep into the dermis with the preservation of the stratum corneum and epidermis. The barrier function of the skin could be recovered 8–60 h post-irradiation depending on the laser spot densities. The application of the laser caused no local infection of Staphylococcus aureus and Pseudomonas aeruginosa. Compared to intact skin, ALA flux was enhanced up to 1200-fold after laser exposure. The penetration enhancement level by the laser was decreased following the increase of permeant lipophilicity. The skin accumulation of tretinoin, an extremely lipophilic drug, showed only a 2-fold elevation by laser irradiation. The laser promoted peptide penetration 10-fold compared to the control skin. Skin delivery of dextrans with a molecular weight (MW) of at least 40 kDa could be achieved with the Er:glass laser. QD with a diameter of 20 nm penetrated into the skin with the assistance of the non-ablative laser. The confocal microscopic images indicated the perpendicular and lateral diffusions of dextrans and nanoparticles via laser-created microscopic thermal zones. Controlled Er:glass laser irradiation offers a valid enhancement strategy to topically administer the permeants with a wide MW and lipophilicity range.",
keywords = "Cutaneous delivery, Macromolecule, Nanoparticle, Non-ablative fractional laser, Small-molecule drug",
author = "Lee, {Woan Ruoh} and Shen, {Shing Chuan} and Aljuffali, {Ibrahim A.} and Lin, {Yin Ku} and Huang, {Chang Wei} and Fang, {Jia You}",
year = "2016",
month = "9",
day = "20",
doi = "10.1016/j.ejps.2016.06.016",
language = "English",
volume = "92",
pages = "1--10",
journal = "European Journal of Pharmaceutical Sciences",
issn = "0928-0987",
publisher = "Elsevier",

}

TY - JOUR

T1 - Non-ablative fractional laser assists cutaneous delivery of small- and macro-molecules with minimal bacterial infection risk

AU - Lee, Woan Ruoh

AU - Shen, Shing Chuan

AU - Aljuffali, Ibrahim A.

AU - Lin, Yin Ku

AU - Huang, Chang Wei

AU - Fang, Jia You

PY - 2016/9/20

Y1 - 2016/9/20

N2 - Use of the ablative laser has been approved to enhance topical drug penetration. Investigation into the usefulness of the non-ablative laser for assisting drug delivery is very limited. In this study, we explored the safety and efficacy of the non-ablative fractional erbium:glass (Er:glass) laser as an enhancement approach to promote drug permeation. Both pig and nude mouse skins were employed as transport barriers. We histologically examined the skin structure after laser exposure. The permeants of 5-aminolevulinic acid (ALA), imiquimod, tretinoin, peptide, dextrans and quantum dots (QD) were used to evaluate in vitro and in vivo skin passage. The fractional laser selectively created an array of photothermal dots deep into the dermis with the preservation of the stratum corneum and epidermis. The barrier function of the skin could be recovered 8–60 h post-irradiation depending on the laser spot densities. The application of the laser caused no local infection of Staphylococcus aureus and Pseudomonas aeruginosa. Compared to intact skin, ALA flux was enhanced up to 1200-fold after laser exposure. The penetration enhancement level by the laser was decreased following the increase of permeant lipophilicity. The skin accumulation of tretinoin, an extremely lipophilic drug, showed only a 2-fold elevation by laser irradiation. The laser promoted peptide penetration 10-fold compared to the control skin. Skin delivery of dextrans with a molecular weight (MW) of at least 40 kDa could be achieved with the Er:glass laser. QD with a diameter of 20 nm penetrated into the skin with the assistance of the non-ablative laser. The confocal microscopic images indicated the perpendicular and lateral diffusions of dextrans and nanoparticles via laser-created microscopic thermal zones. Controlled Er:glass laser irradiation offers a valid enhancement strategy to topically administer the permeants with a wide MW and lipophilicity range.

AB - Use of the ablative laser has been approved to enhance topical drug penetration. Investigation into the usefulness of the non-ablative laser for assisting drug delivery is very limited. In this study, we explored the safety and efficacy of the non-ablative fractional erbium:glass (Er:glass) laser as an enhancement approach to promote drug permeation. Both pig and nude mouse skins were employed as transport barriers. We histologically examined the skin structure after laser exposure. The permeants of 5-aminolevulinic acid (ALA), imiquimod, tretinoin, peptide, dextrans and quantum dots (QD) were used to evaluate in vitro and in vivo skin passage. The fractional laser selectively created an array of photothermal dots deep into the dermis with the preservation of the stratum corneum and epidermis. The barrier function of the skin could be recovered 8–60 h post-irradiation depending on the laser spot densities. The application of the laser caused no local infection of Staphylococcus aureus and Pseudomonas aeruginosa. Compared to intact skin, ALA flux was enhanced up to 1200-fold after laser exposure. The penetration enhancement level by the laser was decreased following the increase of permeant lipophilicity. The skin accumulation of tretinoin, an extremely lipophilic drug, showed only a 2-fold elevation by laser irradiation. The laser promoted peptide penetration 10-fold compared to the control skin. Skin delivery of dextrans with a molecular weight (MW) of at least 40 kDa could be achieved with the Er:glass laser. QD with a diameter of 20 nm penetrated into the skin with the assistance of the non-ablative laser. The confocal microscopic images indicated the perpendicular and lateral diffusions of dextrans and nanoparticles via laser-created microscopic thermal zones. Controlled Er:glass laser irradiation offers a valid enhancement strategy to topically administer the permeants with a wide MW and lipophilicity range.

KW - Cutaneous delivery

KW - Macromolecule

KW - Nanoparticle

KW - Non-ablative fractional laser

KW - Small-molecule drug

UR - http://www.scopus.com/inward/record.url?scp=84976501929&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84976501929&partnerID=8YFLogxK

U2 - 10.1016/j.ejps.2016.06.016

DO - 10.1016/j.ejps.2016.06.016

M3 - Article

VL - 92

SP - 1

EP - 10

JO - European Journal of Pharmaceutical Sciences

JF - European Journal of Pharmaceutical Sciences

SN - 0928-0987

ER -